Naltrexone Implant Sustained Release via Polymer Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacological therapies for opioid use disorder require frequent administration and have limitations in maintaining therapeutic levels of naltrexone, leading to high relapse rates and overdose risks due to reduced tolerance after brief abstinence periods.
Innovation Solution
A subcutaneous bioabsorbable implant system using a composition of naltrexone, poly(DL-lactide), and polycaprolactone with anti-biofouling polyethylene glycol, designed for extended release (6 months to over a year) to maintain therapeutic serum levels of naltrexone, preventing relapse and interaction with fentanyl.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If frequent administration of naltrexone is used to maintain therapeutic levels, then therapeutic effectiveness is improved, but patient compliance and treatment continuity deteriorate due to frequent interventions
Solution Approach 1:
The invention segments the total naltrexone dose into multiple smaller doses encapsulated within individual microspheres, which are then collectively implanted as a single system. This segmentation allows the drug to be released in controlled increments over time, maintaining therapeutic levels without requiring frequent patient visits for re-administration.
Solution Approach 2:
The invention performs preliminary action by pre-encapsulating multiple doses of naltrexone within microspheres during manufacturing, and pre-implanting the entire extended-release system in a single procedure. This eliminates the need for subsequent frequent administrations, as the implant gradually releases predetermined doses over months or years.
2Loss of time
If extended release implant is used to maintain therapeutic levels, then treatment continuity is improved, but manufacturing complexity increases due to homogeneous composition requirements
Solution Approach 1:
The invention changes the physical state parameters of naltrexone during encapsulation, utilizing phase transitions from solid to molten state and controlled crystallization. By precisely controlling temperature, cooling rate, and solvent evaporation parameters during the encapsulation process, the invention achieves homogeneous distribution of naltrexone within microspheres while maintaining manufacturability.
Solution Approach 2:
The invention creates a composite material system where naltrexone is encapsulated within biocompatible polymer microspheres (such as PLGA). This composite structure combines the therapeutic agent with release-controlling materials, enabling extended release while achieving homogeneous composition through controlled manufacturing processes.
3Difficulty of detecting and measuring
If radio-opaque elements are incorporated into the implant, then visualization capability is improved, but biocompatibility may deteriorate due to foreign material presence
Solution Approach 1:
The invention applies local quality by incorporating radio-opaque elements only in specific locations within the implant system (such as within the capsule shell or at specific microsphere clusters) rather than uniformly throughout. This localized approach provides sufficient fluoroscopic visualization while minimizing the total amount of foreign material present, thereby reducing potential foreign-body reactions.
Solution Approach 2:
The invention uses biocompatible, biodegradable radio-opaque materials (such as biodegradable polymers containing iodine or barium compounds) that serve their visualization purpose temporarily during the implant's early period and then degrade harmlessly. These short-living radio-opaque agents provide necessary imaging capability while minimizing long-term foreign material presence.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implant system provides sustained release of naltrexone, reducing relapse rates and overdose risks by maintaining effective serum concentrations for an extended period, facilitating long-term opioid addiction treatment without the need for frequent interventions.
Implementation Method 1
the medicinal agent egresses from the implant's outermost surface as it undergoes non-enzymatic hydrolysis of ester linkages via a combination of surface and bulk erosion over time
Implementation Method 2
the release profile and the pharmacokinetics (PK) are controlled and optimized by a specific composition and weight percentage of the implant's composition and release controlling polymeric compounds
Data Source
AI summary
A method of fabricating an extended release subcutaneous medicinal dosage implant system which includes an implant fabricated from a highly homogeneously mixed composition including a medicinal agent in combination with release controlling polymers which include poly (DL-lactide) and polycaprolactone. In one implementation for treating an opioid disease, the formulation composition includes naltrexone at 40 weight percent, poly (DL-lactide) in the approximate range between 36 and 46.4 weight percent, and polycaprolactone in the approximate range between 24 and 11.6 weight percent. In addition, in order to provide anti-biofouling quality and prevent foreign body adsorption/interaction with the material of the implant, polyethylene glycol is added in a preferred content of 2.0%. The manufacturing process includes hot melt extrusion and a mini jet based implant formation stage with the optimized process space were the temperature of the process ranges from 170° C.-180° C., mixing time through the HME process ranging from 8 minutes to 12 minutes, and injection time ranging from 8 seconds to 12 seconds. The resulting implants have a uniquely shaped free of defects bio absorbable solid body.